[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.87.3. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 647
Citations 0
News From the Food and Drug Administration
November 3, 2015

Expanding the Diabetes Arsenal

JAMA. 2015;314(17):1789. doi:10.1001/jama.2015.13699

Two new drugs used to improve blood glucose control in adults with type 1 or type 2 diabetes have received FDA approval (http://1.usa.gov/1Fmn83O).

Insulin degludec, marketed as Tresiba, is indicated for use alone, with oral diabetes medications, or with bolus insulin. Manufacturer Novo Nordisk of Plainsboro, New Jersey, said in a statement that the drug is the first new basal insulin molecule the FDA has approved in 10 years (http://bit.ly/1VftclJ). Given once daily by injection, insulin degludec’s duration of action is at least 42 hours—much longer than other types of insulin—and it can be taken at any time of day.

First Page Preview View Large
First page PDF preview
First page PDF preview
×